Health Care·Health Care Supplies·$37.8B
Medline Inc A (MDLN) is a leading provider of health care supplies, serving hospitals, nursing homes, and other medical facilities. With a market cap of $38 billion, the company plays a crucial role in the health care sector, especially as demand for medical supplies continues to grow amid ongoing health challenges.
Earnings Per Share (EPS)
EPS is a key indicator of profitability and will show how well Medline is managing costs and generating income.
Revenue
Revenue reflects the overall sales performance and demand for Medline's products, which is critical for assessing growth.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
0%
Avg EPS Surprise
-104.24%
Avg Stock Reaction
-3.62%
In Q4-2025, Medline reported an EPS of -$0.01, significantly missing the expected $0.24. This disappointing performance led to a 3.62% drop in stock price the following day.
Management Promises & Guidance
Analysts are cautiously optimistic about Medline's upcoming earnings, with a consensus EPS of $0.29 and revenue expectations of $7.2 billion. However, the recent earnings miss raises concerns about the company's ability to meet these targets.
Bull Case
If Medline can exceed the EPS and revenue estimates, it could signal a recovery in profitability and operational efficiency, boosting investor confidence.
Bear Case
Conversely, another earnings miss could further undermine investor trust, especially given the company's recent performance and the lack of management guidance.
Earnings Per Share (EPS)
$0.29EPS is a key indicator of profitability and will show how well Medline is managing costs and generating income.
Revenue
$7.2BRevenue reflects the overall sales performance and demand for Medline's products, which is critical for assessing growth.
The print will turn on these two things.
Q1
Will Medline achieve an EPS of at least $0.29?
This figure is critical for restoring investor confidence after the significant miss last quarter.
Q2
What revenue growth can Medline report this quarter?
Meeting or exceeding the $7.2 billion revenue target will indicate strong demand for their products and overall business health.
Why consensus could be wrong
The consensus may underestimate Medline's ability to rebound from last quarter's miss, as operational improvements could lead to better-than-expected results.
Supporting Evidence
The company's historical performance shows it can bounce back from misses, as seen in previous quarters.
Despite recent challenges, demand for health care supplies remains strong, which could positively impact revenue.
Analysts may not fully account for potential cost-cutting measures that could enhance profitability.
Key Risk
If Medline's revenue comes in below $7.1 billion, it could invalidate the recovery narrative.
Pre-commit to what would confirm each case.
This quarter's performance is pivotal as it will reflect Medline's ability to recover from previous setbacks and meet market expectations.
Bull Confirmed If
Achieving an EPS above $0.29 and revenue exceeding $7.2 billion would confirm a positive turnaround.
Bear Confirmed If
An EPS below $0.29 and revenue falling short of $7.2 billion would reinforce concerns about operational challenges.
Implied Move
±4.2%
Currently, there is no options market data available, making it difficult to gauge investor sentiment through options pricing.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Medline beats expectations, history suggests a potential stock increase of about 3.6%, confirming a recovery narrative.
In-Line / Cautious
If results are in line with expectations, the stock may see muted movement as investors await clearer guidance.
Miss
Should the company miss again, history indicates a likely drop of around 3.6%, further eroding investor confidence.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026